02/10/2026
Pathology margin assessment in breast-conserving surgery continues to face critical limitations—including false readings, tissue distortion, and the inability to fully evaluate the specimen surface. These gaps leave room for residual disease to go undetected.
Advances in intraoperative imaging enable real-time scanning inside the breast cavity, providing surgeons with immediate insight into residual cancer that traditional methods may miss.
Lumicell’s intraoperative adjunct visualization technology is designed to illuminate residual breast cancer when surgical decisions matter most.